Table 1.
Characteristics of the Participants Used for Trajectory Assessment Before PDM and Diabetes
| Variable | Cohorts Used for Trajectory Assessment Before PDM | Cohorts Used for Trajectory Assessment Before Diabetes | ||
|---|---|---|---|---|
| PDM-Progressors (n = 4781) | NGR-Nonprogressors (n = 10,994) | DM-Progressors (n = 1061) | NDM-Nonprogressors (n = 26,331) | |
| Males, n (%) | 2,554 (53.4%) | 6,094 (55.4%) | 743 (70.0%) | 15,154 (57.6) |
| Age (y) | 49 (42–55) | 44 (38–52) | 53 (46–60) | 48 (41–56) |
| BMI (kg/m2) | 22.5 (20.6–24.6) | 21.8 (20.1–23.8) | 24.8 (22.5–27.3) | 22.5 (20.6–24.6) |
| SBP (mmHg) | 119 (109–130) | 116 (106–127) | 127 (117–138) | 119 (109–131) |
| FPG (mg/dL) | 92 (89–96) | 90 (86–94) | 106 (99–114) | 93 (89–99) |
| HbA1c (%) | 5.5 (5.2–5.6) | 5.2 (5.1–5.5) | 6.0 (5.7–6.2) | 5.5 (5.2–5.7) |
| HDL-c (mg/dL) | 60 (50–71) | 60 (51–71) | 53 (44–63) | 59 (49–69) |
| LDL-c (mg/dL) | 118 (100–139) | 111 (92–131) | 127 (108–151) | 117 (98–139) |
| TG (mg/dL) | 84 (60–121) | 76 (55–110) | 121 (84–169) | 85 (61–126) |
| ALT (U/L) | 19 (14–27) | 18 (14–25) | 26 (18–38) | 19 (15–27) |
| SPISE | 8.15 (6.73–9.81) | 8.71 (7.20–10.38) | 6.43 (5.40–7.82) | 8.10 (6.67–9.82) |
| Follow up (examination no./y) | 5.5/6.2 | 4.4/5.1 | 4.2/4.2 | 4.8/5.2 |
All variables for progressors and nonprogressors were significantly different (P < 0.01) except for HDL-c in PDM-Progressors and NGR-Nonprogressors. Values are median (25% to 75%), except for categorical data, which are shown as number and percent. Values for follow up represent the mean.
Abbreviations: LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure.